Canada — Health Canada & Dane Stevens

Canada — Health Canada: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, is leading the company's ibogaine initiative and highlights the growing interest and public funding for ibogaine research.

Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.

Canada — Health Canada: Canada — Health Canada has issued a Drug Establishment License (DEL) to Optimi Health Corp., allowing it to produce and distribute regulated psychedelic drug products.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health Corp., announced the launch of the new microdose psilocybin products, highlighting their consistent dosage for controlled research.

Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence for Optimi Health's facility and the export authorization for the psilocybin shipment to Australia, regulating the production and export of these controlled substances.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, expressed pride in the company's commercial supply of psilocybin and highlighted Australia's role as a model for regulated psychedelic medicine.

Dane Stevens: Dane Stevens, CEO of Optimi Health, highlighted the significance of the production and export runs in expanding access to psychedelic treatments in Australia.